OR WAIT null SECS
Trial results could answer questions regarding reports of serious blood clots
AstraZeneca Plc is preparing to file for emergency use authorization (EUA) for its Covid-19 vaccine in the US later this month or early April after gathering enough data to evaluate the dose’s efficacy, sources told Reuters. The AstraZeneca vaccine, which was developed with Oxford University, has been authorized for use in the European Union and various nations.
Two sources with knowledge of the trial expressed to the news outlet that the pharma company completed enrollment in its trial of more than 32,000 volunteers in January and now has data on at least 150 cases of Covid-19. The number of Covid-19 cases among those who got the vaccine versus infections in participants who received a placebo will show how effective the AstraZeneca shot was at preventing illness in those age 18 and over.
US trial results could also help settle concerns arising over reports of serious blood clots in some individuals that have caused several countries to pause administering the vaccine.
Back in February, AstraZeneca mentioned that it could immediately deliver 30 million doses to locations around the US upon receiving the EUA.